Precision Medicine: Diagnostics & Therapeutics

Pair precision-diagnostic businesses with therapeutic developers and the laboratory infrastructure supporting treatment selection and clinical research. This is a diagnostics-to-treatment basket rather than a pure drugmaker or computational drug-discovery portfolio. Lilly's recent dermatology data announcement provides a company-specific catalyst for therapeutic pipeline renewal, while the diagnostic holdings add exposure to molecular testing and disease characterization. Catalysts: - 2026-10-05 LLY: Lilly to present new dermatology data at Fall Clinical 2026 (https://www.barchart.com/press-releases/4959035/lilly-to-present-new-data-across-its-dermatology-portfolio-with-21-presentations-at-fall-clinical-2026-in-pursuit-of-advancing-care-for-chronic-skin-conditions) Launch basket (equal weight): MRK, LLY, AMGN, ABBV, TMO, GH, NTRA, TEM, ILMN, BMY Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.